Field Use Portable Diagnostic Analyzer Guide by Poclight

  • This topic is empty.
Viewing 1 post (of 1 total)
  • Author
    Posts
  • #153187
    admin
    Keymaster

      Understanding the Need for Field-Use Portable Diagnostic Analyzers

      Healthcare delivery outside of centralized hospital laboratories faces a persistent set of operational challenges. Traditional chemiluminescence immunoassay (CLIA) systems depend on complex liquid paths and washing steps, which require specialized infrastructure, trained technicians, and ongoing maintenance. In addition, conventional reagents typically require cold chain logistics, driving up transportation costs and limiting deployment in remote or resource-constrained settings. For emergency departments, small clinics, and decentralized health centers, slow turnaround times and space constraints further compound these issues. Any viable field-use diagnostic solution must therefore address portability, operational simplicity, logistics cost, and speed simultaneously.

      Nanjing Poclight Biotechnology Co., Ltd., operating under the brand Poclight Biotechnology, has positioned itself as an innovative R&D enterprise specializing in 5th generation In Vitro Diagnostic (IVD) platforms. Headquartered in Nanjing, China, the company serves global healthcare markets with a strong focus on South Asia, Southeast Asia, the Middle East, Africa, and Latin America, working through distributors and healthcare partners to expand access to advanced diagnostic technologies.

      Core Technology Behind Portable CLIA Diagnostics

      At the center of Poclight’s platform is its patented Chemiluminescence Resonance Energy Transfer (CRET) technology, a proprietary, no-wash, no-separation homogeneous immunoassay method. Unlike traditional magnetic bead-based assays that require multiple washing and separation steps, the CRET principle uses Acridine Ester and Graphene Oxide quenching to achieve high sensitivity without magnetic beads. This technical approach results in a 70% reduction in time and expenditure for clinical testing compared to conventional methods.

      Poclight has stated that it holds the sole authorized CRET patent for IVD applications worldwide, a distinction that underpins its technology platform’s market differentiation. The CRET technology is made available for technology licensing and integrated solutions, and is adaptable across IVD manufacturing, clinical research, and rapid diagnostic development.

       

      The C5000 Micro-Chemiluminescence Immunoassay Analyzer

      For organizations evaluating field-use portable diagnostic analyzers, the C5000 Micro-Chemiluminescence Immunoassay Analyzer represents Poclight’s flagship hardware product. It is a compact, semi-automated benchtop device engineered for quantitative biomarker detection in settings where space and speed are both limiting factors.

      Key Technical Specifications

      • Results delivered in 3–15 minutes, directly addressing the need for rapid turnaround in emergency and point-of-care environments.
      • Instrument weight of approximately 8.5kg, representing an 80% weight reduction compared to traditional analyzers.
      • A4 footprint, allowing deployment in small clinics and decentralized health centers where bench space is limited.
      • Photon Multiplier Tube (PMT) detection, which provides high sensitivity to ensure lab-grade accuracy despite the device’s compact size.
      • Simple 3-step semi-automated operation, reducing the operational complexity typically associated with traditional CLIA systems.
      • Maintenance-free design with no internal liquid path, eliminating the hidden cleaning and repair costs common to conventional analyzers.

      These features collectively address three distinct pain points. For emergency and bedside settings, the 3-15 minute results window supports faster clinical decision-making. For small clinics facing space constraints, the A4-sized footprint and 8.5kg weight make deployment practical. For clinical laboratories concerned with ongoing operating costs, the maintenance-free operation without liquid paths removes a significant source of hidden expense.

      The C5000 has been adapted for use across a broad range of clinical environments, including ICU, Emergency Departments, Cardiology, Oncology, Pediatrics, Primary Care, and Veterinary Medicine, reflecting the versatility required of a true field-ready diagnostic instrument.

      Reagent Design: Removing the Cold Chain Barrier

      A portable analyzer alone does not solve the logistics problem faced by field diagnostics; the reagents used with it must also be field-compatible. Poclight addresses this through its lyophilized spherical beads, a room-temperature stable reagent format for homogeneous immunoassays.

      These reagents remain stable at 2-30°C for 18 months, which eliminates the need for cold chain shipping and storage. According to Poclight, this design results in a 50% reduction in logistics costs for global shipping, while the 18-month stability window gives remote or resource-limited clinics meaningful flexibility in inventory planning.

      The reagent portfolio supports more than 50 biomarkers, spanning inflammation, cardiac, thyroid, and hormone testing categories, among others. The broader Poclight reagent menu, compatible with its micro CLIA platform, covers nine major clinical diagnostic application areas:

      • Inflammation and infection diagnostics (including CRP, PCT, IL-6, SAA, and HBP)
      • Cardiovascular disease diagnostics (including hs-cTnT, D-Dimer, CK-MB, MYO, NT-proBNP, and BNP)
      • Thyroid function testing (TSH, TT3, TT4, FT3, FT4)
      • Fertility and hormone testing (AMH, FSH, LH, E2, Progesterone, Prolactin, Testosterone, Cortisol, β-hCG, Folate)
      • Diabetes and metabolic testing (HbA1c, Insulin, Ferritin)
      • Bone metabolism and vitamin testing (25-OH VD)
      • Tumor marker testing (PSA, fPSA, CEA, AFP, CA125, CA15-3, CA19-9, CYFRA21-1)
      • Respiratory and specialized diagnostics (KL-6)
      • Platelet function and coagulation-related testing (CD41, CD45, CD61, CD42a, CD42b, PAC-1, CD62P, AA- and ADP-induced platelet activation testing)

      This breadth means a single compact platform can support quantitative detection across more than 50 parameters, which is a meaningful consideration for field operations that need to consolidate multiple testing needs into one deployable system.

      Documented Use Cases in the Field

      Poclight’s technology has been applied across several real-world scenarios that illustrate the practical value of portable diagnostic analyzers:

      In emergency chest pain centers, implementation of ultra-fast CLIA point-of-care testing has supported a substantial reduction in door-to-balloon time, a critical metric in acute cardiac care. In community health centers, the combination of the C5000 and lyophilized reagents has brought CLIA-level sensitivity to primary care settings without requiring large infrastructure investments. For ICU sepsis management, the synergy of PCT and IL-6 testing has helped accelerate clinical decision-making for rapid infection response. In decentralized women’s care settings, benchtop CLIA integration has enabled lab-quality endocrine and fertility monitoring directly within clinic environments.

      Quality Assurance and Market Standing

      Poclight’s platform operates under adherence to ISO 13485 quality management standards, and the company holds CE Certification, ISO 13485 Certification, NMPA certification, and NGSP certification. These certifications provide a framework for data security, compliance, and consistent quality management across its product lines.

      Business Model Considerations for Adopters

      Organizations evaluating field-use diagnostic analyzers often weigh total cost of ownership alongside upfront pricing. Poclight’s approach emphasizes low-cost diagnostic solutions with zero hidden maintenance costs, a direct result of the maintenance-free instrument design with no internal liquid path. The company also offers equipment sales, reagent supply, and OEM/ODM services, giving distributors and healthcare partners flexibility in how they bring the technology to their markets. Deployment options include benchtop and portable configurations, with no cold chain logistics required for reagent handling.

      Conclusion

      For stakeholders researching field-use portable diagnostic analyzers, the combination of compact hardware, room-temperature stable reagents, and a no-wash, no-separation CRET-based testing process addresses the core operational barriers that have historically limited decentralized diagnostics: space, speed, logistics cost, and maintenance burden. Poclight Biotechnology’s C5000 Micro-Chemiluminescence Immunoassay Analyzer, supported by its lyophilized reagent portfolio and proprietary CRET technology platform, offers a documented framework for extending CLIA-level diagnostic capability into emergency departments, primary care settings, veterinary practices, and decentralized health centers worldwide.

       

      http://www.poclight.com
      Nanjing Poclight Biotechnology Co., Ltd

    Viewing 1 post (of 1 total)
    • You must be logged in to reply to this topic.